Patents

BioCancell Therapeutics holds the following granted and pending patents:

• Use of the H19 gene as a tumor marker

• Methods and compositions for inducing tumor-specific cytotoxicity

• Method for detection of micro-metastasis

• H19 siRNA for treatment of cancer

• Methods and composition for inducing selective expression in tumor cells of the A subunit of the Diphtheria Toxin and the TNF alpha genes under the control of H19 promoter (H19 + TNF alpha)